Amgen Inc. Business Combination, Contingent Consideration, Liability
Amgen Inc. (AMGN) had Business Combination, Contingent Consideration, Liability of $171.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:BusinessCombinationContingentConsiderationLiability · last filed 2026-08-05
- 2026-06-30: Business Combination, Contingent Consideration, Liability $171.00M.
- 2026-03-31: Business Combination, Contingent Consideration, Liability $173.00M.
- 2025-12-31: Business Combination, Contingent Consideration, Liability $161.00M.
- 2025-09-30: Business Combination, Contingent Consideration, Liability $95.00M.
| Period end | Business Combination, Contingent Consideration, Liability | Business Combination, Contingent Consideration, Liability as first filed |
|---|---|---|
| 2026-06-30 | $171.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $173.00M 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $161.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $95.00M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $90.00M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $104.00M 10-Q · filed 2025-05-02 | |
| 2024-12-31 | $106.00M 10-K · filed 2026-02-13 | |
| 2024-09-30 | $112.00M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $107.00M 10-Q · filed 2024-10-31 | |
| 2024-03-31 | $96.00M 10-Q · filed 2024-08-07 | |
| 2023-12-31 | $96.00M 10-K · filed 2026-02-13 | |
| 2023-09-30 | $98.00M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $248.00M 10-Q · filed 2024-10-31 | |
| 2023-03-31 | $273.00M 10-Q · filed 2024-08-07 | |
| 2022-12-31 | $270.00M 10-K · filed 2025-02-14 | |
| 2022-09-30 | $302.00M 10-Q · filed 2023-10-31 | |
| 2022-06-30 | $310.00M 10-Q · filed 2023-10-31 | |
| 2022-03-31 | $330.00M 10-Q · filed 2023-08-04 | |
| 2021-12-31 | $342.00M 10-K · filed 2025-02-14 | |
| 2021-09-30 | $35.00M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $48.00M 10-Q · filed 2022-11-04 | |
| 2021-03-31 | $39.00M 10-Q · filed 2022-08-05 | |
| 2020-12-31 | $33.00M 10-K · filed 2024-02-14 | |
| 2020-09-30 | $54.00M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $55.00M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $60.00M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $61.00M 10-K · filed 2023-02-09 | |
| 2019-09-30 | $62.00M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $63.00M 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $66.00M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $72.00M 10-K · filed 2022-02-16 | |
| 2017-12-31 | $69.00M 10-K · filed 2019-02-13 | $0.00 10-Q · filed 2018-10-31 |
| 2016-12-31 | $116.00M 10-Q · filed 2018-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |